Skip to Content

Isturisa (osilodrostat) Disease Interactions

There are 4 disease interactions with Isturisa (osilodrostat):

Moderate

Osilodrostat (Includes Isturisa) ↔ hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Dosage adjustment of osilodrostat is required for patients with moderate to severe hepatic impairment. The recommended starting dose for patients with moderate hepatic impairment is 1 mg twice daily, and for patients with severe hepatic impairment is 1 mg once daily in the evening. No dose adjustment is required in patients with mild hepatic impairment. It is recommended to monitor more frequent adrenal function during dose titration in all patients with hepatic impairment.

Moderate

Osilodrostat (Includes Isturisa) ↔ renal impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

No dosage adjustment of osilodrostat is required for patients with impaired renal function. However, in patients with moderate to severe renal impairment, urinary free cortisol (UFC) levels should be interpreted with caution due to reduced UFC excretion.

Moderate

Osilodrostat – arrhythmias

Moderate Potential Hazard, Moderate plausibility. Applies to: Arrhythmias, Congestive Heart Failure, Electrolyte Abnormalities, Hypokalemia, Magnesium Imbalance

The use of osilodrostat may cause dose-dependent QT interval prolongation and cardiac arrhythmias. Care should be exercised when using this agent in patients with risk factors for QT prolongation. It is recommended to obtain a baseline QTc interval measurement before starting therapy and monitor ECG periodically as clinically appropriate. Consider therapy discontinuation in case of an increase in QTc interval > 480 ms. Correct hypokalemia and hypomagnesemia before initiating treatment and monitor regularly during treatment. Correct electrolyte abnormalities if indicated.

Moderate

Osilodrostat – hypocortisolism

Moderate Potential Hazard, Moderate plausibility. Applies to: Adrenal Insufficiency

Osilodrostat lowers cortisol levels and can lead to hypocortisolism and sometimes life-threatening adrenal insufficiency. Evaluate patients for precipitating causes of hypocortisolism. Monitor 24-hour urine free cortisol, serum or plasma cortisol, and patient's signs and symptoms periodically during treatment. Decrease or temporarily discontinue treatment if urine free cortisol levels fall below the target range, there is a rapid decrease in cortisol levels, or patients report hypocortisolism symptoms. Stop treatment and administer exogenous glucocorticoid replacement therapy if serum or plasma cortisol levels are below the target range. Re-initiate therapy at a lower dose when urine free cortisol, serum or plasma cortisol levels are within the target range, or patient symptoms have resolved.

Isturisa (osilodrostat) drug interactions

There are 408 drug interactions with Isturisa (osilodrostat)

Isturisa (osilodrostat) alcohol/food interactions

There is 1 alcohol/food interaction with Isturisa (osilodrostat)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.